A detailed history of Janney Montgomery Scott LLC transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Janney Montgomery Scott LLC holds 27,158 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,158
Previous 29,158 6.86%
Holding current value
$0
Previous $423,000 32.15%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 17, 2025

SELL
N/A
-2,000 Reduced 6.86%
27,158 $287,000
Q3 2024

Oct 29, 2024

BUY
N/A
4,672 Added 19.08%
29,158 $423,000
Q1 2024

May 01, 2024

BUY
N/A
881 Added 3.73%
24,486 $250,000
Q4 2023

Feb 07, 2024

SELL
N/A
-467 Reduced 1.94%
23,605 $129,000
Q3 2023

Nov 08, 2023

SELL
N/A
-15,897 Reduced 39.77%
24,072 $91,000
Q2 2023

Jul 26, 2023

SELL
N/A
-10,274 Reduced 20.45%
39,969 $268,000
Q1 2023

Apr 28, 2023

SELL
N/A
-3,471 Reduced 6.46%
50,243 $327,000
Q4 2022

Feb 01, 2023

SELL
$0.0 - $6.07 $0 - $171,896
-28,319 Reduced 34.52%
53,714 $458,000
Q3 2022

Oct 25, 2022

SELL
$3.91 - $5.52 $25,121 - $35,466
-6,425 Reduced 7.26%
82,033 $433,000
Q2 2022

Aug 03, 2022

BUY
$2.9 - $4.44 $11,286 - $17,280
3,892 Added 4.6%
88,458 $379,000
Q1 2022

May 04, 2022

SELL
$3.51 - $6.74 $579 - $1,112
-165 Reduced 0.19%
84,566 $297,000
Q4 2021

Jan 27, 2022

BUY
$6.03 - $11.67 $417,294 - $807,599
69,203 Added 445.67%
84,731 $564,000
Q3 2021

Oct 29, 2021

SELL
$9.98 - $35.22 $5,788 - $20,427
-580 Reduced 3.6%
15,528 $155,000
Q2 2021

Jul 26, 2021

BUY
$24.71 - $44.28 $6,128 - $10,981
248 Added 1.56%
16,108 $498,000
Q1 2021

Apr 27, 2021

BUY
$37.62 - $60.41 $184,450 - $296,190
4,903 Added 44.75%
15,860 $692,000
Q4 2020

Jan 25, 2021

BUY
$25.0 - $46.34 $273,925 - $507,747
10,957 New
10,957 $508,000

Others Institutions Holding SBTX

About Silverback Therapeutics, Inc.


  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track Janney Montgomery Scott LLC Portfolio

Follow Janney Montgomery Scott LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janney Montgomery Scott LLC, based on Form 13F filings with the SEC.

News

Stay updated on Janney Montgomery Scott LLC with notifications on news.